ABSTRACT
The lack of access to medicines is one of the most intractable challenges in Africa. It has serious socio-economic and health implications that negatively affect the economic development and public health security beyond the continent. Notwithstanding its importance, such complex problems are mostly ignored due to the “silent complicity” of corporate responsibility (CR) researchers on one hand and actors in public health governance on the other. In a measured manner that respects the canons of validity of interpretive research, I critique the evidential shortcomings in pharmaceutical business–society relations. Here, post-colonial theory is employed as a theoretical foundation for the empirical analysis. I present the results of an empirical case study of a Ghanaian pharmaceutical firm whose responsible leadership and development-oriented CR activities meaningfully redefines the contours of pharmaceutical business–society nexus through new value propositions that serve as a paradigm shift to the status quo.
